Udayavni Special

US FDA rejects emergency authorisation for Covaxin, ‘recommends’ to take full approval route


PTI, Jun 11, 2021, 12:46 PM IST

Hyderabad: In a setback to Bharat Biotech’s COVID-19 vaccine Covaxin, the US Food and Drug Administration has “recommended” Ocugen Inc, the US partner of the Indian vaccine maker, to go for Biologics Licence Application (BLA) route with additional data, nixing hopes of Emergency Use Authorisation.

Ocugen in a statement on Thursday announced that as recommended by the FDA, it will pursue submission of a biologics licence application (BLA) for Covaxin.

BLA, is a “full approval” mechanism by the FDA for drugs and vaccines.

“The company will no longer pursue an Emergency Use Authorization (EUA) for Covaxin. The FDA provided feedback to Ocugen regarding the Master File. The company had previously submitted and recommended that Ocugen pursue a BLA submission instead of an EUA application for its vaccine candidate and requested additional information and data,” Ocugen said.

The development may delay the Covaxin launch in the US, Ocugen said.

Ocugen is in discussions with the FDA to understand the additional information required to support a BLA submission.

The company anticipates that data from an additional clinical trial will be required to support the submission.

“Although we were close to finalising our EUA application for submission, we received a recommendation from the FDA to pursue a BLA path. While this will extend our timelines, we are committed to bringing Covaxin to the US,” Dr.

Shankar Musunuri, Chairman of the Board, Chief Executive Officer and co-founder of Ocugen said.

“This differentiated vaccine is a critical tool to include in our national arsenal given its potential to address the SARS-CoV-2 variants, including the delta variant, and given the unknowns about what will be needed to protect US population in the long term,” he added.

Ocugen recently announced that it secured exclusive rights to commercialise Covaxin in Canada and has initiated discussions with Health Canada for regulatory approval.

The company will pursue expedited authorisation for the vaccine under the Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19 in Canada.

Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.

Top News

Chhetri extends contract with Bengaluru FC for another two years

Bengaluru: 5 people try to sacrifice 10-yr-old to ‘ward off spirits’; arrested

Don’t be under illusion that COVID-19 is gone, CM BSY’s warns as restrictions ease

‘Vaccination hesitation is coronavirus invitation’: Naqvi at launch of awareness campaign

Man given two doses of COVID vaccine in 30 minutes duration

SC asks Centre if PM-headed NDMA decided on ex-gratia compensation to families of COVID victims

Facebook, WhatsApp urge HC to stay CCI notice in privacy policy matter



MUST WATCH

Yoga at Work Place

Udayavani News Bulletin 20-JUN-2021

Manipal IT youngsters plants trees | Planting trees to preserve the Environment

Police Sub Inspector angry on Farmers in Raichur

Belgaum Rescue operation

Latest Additions

Net profit of big cement firms surges 29.6% in pandemic-hit FY21: Report

When Madhavrao Scindia staged a ‘dacoity’ to spook Indian cricket stars

Chhetri extends contract with Bengaluru FC for another two years

Iran’s president-elect defends himself over 1988 executions

Bengaluru: 5 people try to sacrifice 10-yr-old to ‘ward off spirits’; arrested

Thanks for visiting Udayavani

You seem to have an Ad Blocker on.
To continue reading, please turn it off or whitelist Udayavani.